14 Cathie Wood Verve Therapeutics Trades
Cathie Wood started to build up the position in Verve Therapeutics in Q2 2021 and continued to invest until Q4 2023. Since then they sold 7.03 Million shares. The investor completely sold their stake between Q1 2024 and Q3 2024.
Avg closing price
Price range
Sold -2.94 Million shares
Q3 2024
Avg closing price
$5.81
Price range
$4.40
-
$7.86
Sold 51.4% shares (-3.1 Million shares)
Q2 2024
Avg closing price
$6.29
Price range
$4.76
-
$12.79
Sold 14.0% shares (-985 Thousand shares)
Q1 2024
Avg closing price
$13.26
Price range
$10.81
-
$17.96
Increased shares by 35.1% (+1.82 Million shares)
Q4 2023
Avg closing price
$12.40
Price range
$8.84
-
$18.70
Increased shares by 1.0% (+49.7 Thousand shares)
Q3 2023
Avg closing price
$16.10
Price range
$11.42
-
$20.82
Increased shares by 14.9% (+669 Thousand shares)
Q2 2023
Avg closing price
$16.65
Price range
$13.34
-
$19.90
Increased shares by 2.7% (+116 Thousand shares)
Q1 2023
Avg closing price
$19.58
Price range
$14.30
-
$24.01
Increased shares by 28.6% (+972 Thousand shares)
Q4 2022
Avg closing price
$26.50
Price range
$17.85
-
$40.70
Increased shares by 66.8% (+1.36 Million shares)
Q3 2022
Avg closing price
$31.92
Price range
$15.63
-
$41.49
Increased shares by 20.6% (+347 Thousand shares)
Q2 2022
Avg closing price
$15.49
Price range
$11.14
-
$23.17
Increased shares by 20.5% (+287 Thousand shares)
Q1 2022
Avg closing price
$28.58
Price range
$20.92
-
$39.36
Increased shares by 10.4% (+132 Thousand shares)
Q4 2021
Avg closing price
$42.01
Price range
$31.94
-
$54.82
Increased shares by 131.2% (+719 Thousand shares)
Q3 2021
Avg closing price
$58.83
Price range
$46.00
-
$73.99
New holding (+548 Thousand shares)
Q2 2021
Avg closing price
$41.51
Price range
$31.92
-
$60.25
News about Verve Therapeutics Inc and Cathie Wood
Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On
Cathie Wood, the brilliant mind behind ARK Invest , is known for her unique ability to spot disruptive trends in stocks. Her investment strategies have made ...
Verve: Spiffy Biotech That Cathie Wood Bought, Initiating With A Hold Rating (NASDAQ:VERV)
Verve Therapeutics is developing a CRISPR-based gene therapy for cardiovascular diseases. Click here for our take on VERN assets and stock prospects.